Chlamydia Trachomatis Momp Antibody (1297/143) - BSA Free

• Reactivity: Ba
• Applications: WB, ELISA
• Clone: 1297/143
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

Chlamydia Trachomatis Momp Antibody (1297/143) - BSA Free Summary

• Immunogen: Native MOMP, serovar E, from Chalmydia trachomatis
• Specificity: Reacts with MOMP from C. trachomatis.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Western Blot 1:100-1:2000
• Application Notes: This antibody is useful for Western Blot, ELISA. Should this product contain a precipitate, we recommend microcentrifugation before use.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.09% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein A purified

Alternate Names for Chlamydia Trachomatis Momp Antibody (1297/143) - BSA Free

• Major Outer Membrane Protein
• MOMP
• omp1
• omp1F
• Omp1L1
• ompA
• ompIL2

Background

Chlamydia trachomatis is an intracellular organism. Chlamydia usually infects the cervix and fallopian tubes of women and the urethra of men. Chlamydial infections are believed to be one of the most common of all STDs. It is generally thought that in a population of 15 million, there are up to 300,000 cases of chlamydia each year. Thus, there are many undiagnosed cases of chlamydia in the community. It has been estimated that the true prevalence of chlamydia in the sexually active population may be in the order of 5% to 10%. Chlamydia is one of the leading causes of blindness in underdeveloped countries.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Chlamydia Trachomatis Momp Antibody (NB100-66403)(3)

Publications using NB100-66403

• Matthew D. Romero, Rey A. Carabeo Dynamin-dependent entry of Chlamydia trachomatis is sequentially regulated by the effectors TarP and TmeA Nature Communications 2024-06-10 [PMID: 38858371]
• Romero MD, Carabeo RA Dynamin-dependent entry of Chlamydia trachomatis is sequentially regulated by the effectors TarP and TmeA Research square 2023-09-27 [PMID: 37841835] (Monkey)
• Weyant KB, Oloyede A, Pal S et al. A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens Nature Communications 2023-01-28 [PMID: 36709333] (Western Blot, Dot Blot)

FAQs for Chlamydia Trachomatis Momp Antibody (NB100-66403). (Showing 1 - 3 of 3 FAQs).

1. Can you tell me sub-species for Chlamydia Trachomatis Momp Antibody (1297/143), catalog # NB100-66403? Also, how did you check reactivity?
   • NB100-66403 has been tested by ELISA and WB against serotype E, but none others. However, we do have a customer report that they tried testing against all other serovars and were able to see signal. I do not have any additional details regarding our customer testing; I do not know whether they tested other serovars via ELISA or WB.
2. Did you ever try WB for cross-reactivity with E. coli. We are trying to over-express and getting lot of background with in-hand antibodies.
   • We have not tested this antibody on E. coli samples.
3. Could I get more information about this antibody?
   • NB100-66403 was raised against type E MOMP (the major outer membrane) from C. trachomatis. Although both Chiamydia and Escherichia are the Gram Negative bacteria. E. coli has to have the identical type E MOMP to be detected by NB100-66403.

Bioinformatics

• Uniprot:
  • P17451(Human)